表皮生长因子受体敏感突变肺癌靶向治疗原发耐药的机制及临床对策

doi:10.12114/j.issn.1007-9572.2021.00.153

摘要/Abstract

摘要： 针对伴有表皮生长因子受体（EGFR）敏感突变的非小细胞肺癌，基于小分子抑制剂的靶向治疗在临床上取得了极大成效，但仍面临着原发耐药/不敏感的问题。初始治疗的有效比例及疗效深度决定了患者的远期生存。本文梳理了关于原发耐药的主要机制，包括突变亚型结构、原发T790M、合并突变、免疫状态等的影响及其相互关系，以及目前有效药物的证据，提出了多基因分型、精准靶向、“鸡尾酒”疗法等克服原发耐药的管理策略，并展望了该领域的发展趋势，为同行们的临床实践及科研方向提供思路。

本文更多信息：《英国癌症杂志》最新研究表明，常规用药可能会影响肿瘤免疫靶向治疗的效果，为我们敲响了警钟，视频链接为https://www.chinagp.net/CN/news/news15.shtml，点击即可在线观看。

关键词: 肺肿瘤；抗药性, 肿瘤；表皮生长因子受体突变；原发耐药

Abstract: Clinical evidence has showed that targeted therapy with small molecule inhibitors produces good efficacy in patients with non-small cell lung cancer（NSCLC）harboring epidermal growth factor receptor（EGFR）sensitive mutations，but there are also some patients who display primary resistance or insensitivity to the therapy.As the response rate and level to the initial therapy are determinants for patients'long-term survival，we reviewed evidence about major mechanisms leading to primary resistance，including the impact of the structure of EGFR mutation subtypes，primary EGFR T790M mutation，concurrent EGFR mutations，and immune status on the therapy response，as well as their associations，then proposed targeted management strategies，such as treatment targeting the genetic mutation or the mutation site，precise targeted therapy，cocktail therapy and so on，and evaluated the development trend of treatment for primary resistance to targeted therapy.All these aimed at helping medical workers with clinical practice and research.

Key words: Lung neoplasms；Drug resistance, neoplasm；Epidermal growth factor receptor mutation；Primary resistance

梁文华,黎才琛,梁恒瑞,等. 表皮生长因子受体敏感突变肺癌靶向治疗原发耐药的机制及临床对策[J]. 中国全科医学, 2021, 24(8): 901-916. DOI: 10.12114/j.issn.1007-9572.2021.00.153.
LIANG Wenhua,LI Caichen,LIANG Hengrui, et al. Mechanism and Management of Primary Resistance to Targeted Therapy in NSCLC Patients Harboring EGFR Sensitive Mutations　[J]. Chinese General Practice, 2021, 24(8): 901-916. DOI: 10.12114/j.issn.1007-9572.2021.00.153.

参考文献

［1］FITZMAURICE C，ABATE D，ABBASI N，et al．Global，regional，and national cancer incidence，mortality，years of life lost，years lived with disability，and disability-adjusted life-years for 29 cancer groups，1990 to 2017：a systematic analysis for the Global Burden of Disease Study［J］．JAMA Oncol，2019，5（12）：1749-1768．DOI：10.1001/jamaoncol.2019.2996.
［2］CHEN W Q，ZHENG R S，BAADE P D，et al．Cancer statistics in China，2015［J］．CA Cancer J Clin，2016，66（2）：115-132．DOI：10.3322/caac.21338.
［3］WANG H，HUANG J，YU X J，et al．Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer：a meta-analysis［J］．J Cancer Res Clin Oncol，2014，140（11）：1901-1909．DOI：10.1007/s00432-014-1709-0.
［4］WANG J，WANG B C，CHU H L，et al．Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations［J］．Oncotargets Ther，2016：3711-3726．DOI：10.2147/ott.s106399.
［5］KOBAYASHI Y，MITSUDOMI T.Not all epidermal growth factor receptor mutations in lung cancer are created equal：perspectives for individualized treatment strategy［J］．Cancer Sci，2016，107（9）：1179-1186．DOI：10.1111/cas.12996.
［6］YATABE Y，KERR K M，UTOMO A，et al．EGFR mutation testing practices within the Asia Pacific region：results of a multicenter diagnostic survey［J］．J Thorac Oncol，2015，10（3）：438-445．DOI：10.1097/JTO.0000000000000422.
［7］YANG J C，WU Y L，SCHULER M，et al．Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma（LUX-Lung 3 and LUX-Lung 6）：analysis of overall survival data from two randomised，phase 3 trials［J］．Lancet Oncol，2015，16（2）：141-151．DOI：10.1016/S1470-2045（14）71173-8.
［8］ZHANG Y X，SHENG J，KANG S Y，et al．Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer：a meta-analysis［J］．PLoS One，2014，9（9）：e107161．DOI：10.1371/journal.pone.0107161.
［9］LEE C K，WU Y L，DING P N，et al．Impact of specific epidermal growth factor receptor（EGFR）mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer：a meta-analysis［J］．J Clin Oncol，2015，33（17）：1958-1965．DOI：10.1200/jco.2014.58.1736.
［10］LI W Q，CUI J W.Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation：distinct mechanisms，different efficacies to treatments［J］．J Cancer Res Clin Oncol，2020，146（9）：2329-2338．DOI：10.1007/s00432-020-03296-6.
［11］KUMAR A，PETRI E T，HALMOS B，et al．Structure and clinical relevance of the epidermal growth factor receptor in human cancer［J］．J Clin Oncol，2008，26（10）：1742-1751．DOI：10.1200/jco.2007.12.1178.
［12］NIE W W，TANG L，ZHANG H Y，et al．Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy［J］．Int J Oncol，2012，40（6）：1763-1769．DOI：10.3892/ijo.2012.1356.
［13］HONG S D，GAO F F，FU S，et al．Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer［J］．JAMA Oncol，2018，4（5）：739-742．DOI：10.1001/jamaoncol.2018.0049.
［14］YU H A，ARCILA M E，REKHTMAN N，et al．Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers［J］．Clin Cancer Res，2013，19（8）：2240-2247．DOI：10.1158/1078-0432.CCR-12-2246.
［15］ZHONG J，LI L，WANG Z J，et al．Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor receptor（EGFR）tyrosine kinase inhibitors（TKIs）［J］．J Thorac Oncol，2017，12（12）：1766-1778．DOI：10.1016/j.jtho.2017.07.032.
［16］SALDA?A-RIVERA L，BELLO M，MéNDEZ-LUNA D.Structural insight into the binding mechanism of ATP to EGFR and L858R，and T790M and L858R/T790 mutants［J］．J Biomol Struct Dyn，2019，37（17）：4671-4684．DOI：10.1080/07391102.2018.1558112.
［17］YUN C H，MENGWASSER K E，TOMS A V，et al．The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP［J］．Proc Natl Acad Sci USA，2008，105（6）：2070-2075．DOI：10.1073/pnas.0709662105.
［18］TU H Y，KE E E，YANG J J，et al．A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer［J］．Lung Cancer，2017，114：96-102．DOI：10.1016/j.lungcan.2017.11.005.
［19］TIBALDI C，GIOVANNETTI E，VASILE E，et al．Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients［J］．J Thorac Oncol，2011，6（2）：395-396．DOI：10.1097/JTO.0b013e3182059a6f.
［20］LI W H，QIU T，GUO L，et al．Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment［J］．Cancer Lett，2018，423：9-15．DOI：10.1016/j.canlet.2018.03.005.
［21］HU Y B，ALDEN R S，ODEGAARD J I，et al．Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31，414 cancer patients［J］．Clin Cancer Res，2017，23（23）：7351-7359．DOI：10.1158/1078-0432.CCR-17-1745.
［22］LU S，YU Y F，LI Z M，et al．EGFR and ERBB2 germline mutations in Chinese lung cancer patients and their roles in genetic susceptibility to cancer［J］．J Thorac Oncol，2019，14（4）：732-736．DOI：10.1016/j.jtho.2018.12.006.
［23］GIRARD N，LOU E，AZZOLI C G，et al．Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol：a preliminary report［J］．Clin Cancer Res，2010，16（2）：755-763．DOI：10.1158/1078-0432.ccr-09-2437.
［24］WEN S W，DAI L，WANG L，et al．Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer［J］．Oncologist，2019，24（11）：e1070-1081．DOI：10.1634/theoncologist.2018-0572.
［25］SU K Y，CHEN H Y，LI K C，et al．Pretreatment epidermal growth factor receptor（EGFR）T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer［J］．J Clin Oncol，2012，30（4）：433-440．DOI：10.1200/JCO.2011.38.3224.
［26］YANG J C，SEQUIST L V，GEATER S L，et al．Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations：a combined post-hoc analysis of LUX-Lung 2，LUX-Lung 3，and LUX-Lung 6［J］．Lancet Oncol，2015，16（7）：830-838．DOI：10.1016/S1470-2045（15）00026-1.
［27］BLAKELY C M，WATKINS T B K，WU W，et al．Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers［J］．Nat Genet，2017，49（12）：1693-1704．DOI：10.1038/ng.3990.
［28］WANG Z J，CHENG Y，AN T T，et al．Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma（BENEFIT）：a phase 2，single-arm，multicentre clinical trial［J］．Lancet Respir Med，2018，6（9）：681-690．DOI：10.1016/S2213-2600（18）30264-9.
［29］BENEDETTINI E，SHOLL L M，PEYTON M，et al．Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis［J］．Am J Pathol，2010，177（1）：415-423．DOI：10.2353/ajpath.2010.090863.
［30］ENGELMAN J A，ZEJNULLAHU K，MITSUDOMI T，et al．MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling［J］．Science，2007，316（5827）：1039-1043．DOI：10.1126/science.1141478.
［31］LOU N N，WU Y L，YANG J J，et al．Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation［J］．J Clin Oncol，2016，34（15_suppl）：9054.
［32］LIM S M，KIM H R，CHO E K，et al．Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor（Korean Lung Cancer Consortium）［J］．Oncotarget，2016，7（24）：36311-36320．DOI：10.18632/oncotarget.8904.
［33］AISNER D L，SHOLL L M，BERRY L D，et al．The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the lung cancer mutation consortium（LCMC2）［J］．Clin Cancer Res，2018，24（5）：1038-1047．DOI：10.1158/1078-0432.ccr-17-2289.
［34］LABBé C，CABANERO M，KORPANTY G J，et al．Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer（NSCLC）［J］．Lung Cancer，2017，111：23-29．DOI：10.1016/j.lungcan.2017.06.014.
［35］JIN Y，SHI X，ZHAO J，et al．Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas［J］．Lung Cancer，2018，124：110-116．DOI：10.1016/j.lungcan.2018.07.039.
［36］ZHANG R，TIAN P W，CHEN B J，et al．The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients：a systematic review and meta-analysis［J］．Postgrad Med，2019，131（3）：199-206．DOI：10.1080/00325481.2019.1585690.
［37］CANALE M，PETRACCI E，DELMONTE A，et al．Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors［J］．Clin Cancer Res，2017，23（9）：2195-2202．DOI：10.1158/1078-0432.ccr-16-0966.
［38］NG K P，HILLMER A M，CHUAH C T，et al．A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer［J］．Nat Med，2012，18（4）：521-528．DOI：10.1038/nm.2713.
［39］ISOBE K，HATA Y，TOCHIGI N，et al．Clinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation［J］．J Thorac Oncol，2014，9（4）：483-487．DOI：10.1097/jto.0000000000000125.
［40］LEE J H，LIN Y L，HSU W H，et al．Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer［J］．J Thorac Oncol，2014，9（9）：1385-1392．DOI：10.1097/JTO.0000000000000238.
［41］CARDONA A F，ROJAS L，WILLS B，et al．BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations［J］．Oncotarget，2016，7（42）：68933-68942．DOI：10.18632/oncotarget.12112.
［42］YUAN J P，LI B，ZHANG N S，et al．Clinical implications of the BIM deletion polymorphism in advanced lung adenocarcinoma treated with gefitinib［J］．Clin Lung Cancer，2018，19（4）：e431-438．DOI：10.1016/j.cllc.2018.02.007.
［43］COSTA C，MOLINA M A，DROZDOWSKYJ A，et al．The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial［J］．Clin Cancer Res，2014，20（7）：2001-2010．DOI：10.1158/1078-0432.CCR-13-2233.
［44］FABER A C，CORCORAN R B，EBI H，et al．BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors［J］．Cancer Discov，2011，1（4）：352-365．DOI：10.1158/2159-8290.CD-11-0106.
［45］KURODA J，PUTHALAKATH H，CRAGG M S，et al．Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells，and resistance due to their loss is overcome by a BH3 mimetic［J］．Proc Natl Acad Sci USA，2006，103（40）：14907-14912．DOI：10.1073/pnas.0606176103.
［46］NAKAGAWA T，TAKEUCHI S，YAMADA T，et al．EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition［J］．Cancer Res，2013，73（8）：2428-2434．DOI：10.1158/0008-5472.can-12-3479.
［47］TANIMOTO A，TAKEUCHI S，ARAI S，et al．Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-mutant lung cancer［J］．Clin Cancer Res，2017，23（12）：3139-3149．DOI：10.1158/1078-0432.ccr-16-2271.
［48］LEE J K，SHIN J Y，KIM S，et al．Primary resistance to epidermal growth factor receptor（EGFR）tyrosine kinase inhibitors（TKIs）in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations：an exploratory study［J］．Ann Oncol，2013，24（8）：2080-2087．DOI：10.1093/annonc/mdt127.
［49］LEE J Y，KU B M，LIM S H，et al．The BIM deletion polymorphism and its clinical implication in patients with EGFR-mutant non-small-cell lung cancer treated with EGFR tyrosine kinase inhibitors［J］．J Thorac Oncol，2015，10（6）：903-909．DOI：10.1097/JTO.0000000000000535.
［50］WU S G，LIU Y N，YU C J，et al．Association of BIM deletion polymorphism with intrinsic resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma［J］．JAMA Oncol，2016，2（6）：826-828．DOI：10.1001/jamaoncol.2016.0016.
［51］SUN S，YU H，WANG H，et al．Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors［J］．Onco Targets Ther，2017，10：1955-1967．DOI：10.2147/ott.s126075.
［52］LIU S Y，ZHOU J Y，LI W F，et al．Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism［J］．Clin Transl Med，2020，10（1）：337-345．DOI：10.1002/ctm2.12.
［53］LI R，MOUDGIL T，ROSS H J，et al．Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim［J］．Cell Death Differ， 2005，12（3）：292-303．DOI：10.1038/sj.cdd.4401554.
［54］PAO W，CHMIELECKI J．Rational，biologically based treatment of EGFR-mutant non-small-cell lung cancer［J］．Nat Rev Cancer，2010，10（11）：760-774．DOI：10.1038/nrc2947
［55］HSU K H，HUANG Y H，TSENG J S，et al．High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na?ve advanced EGFR-mutant lung adenocarcinoma patients［J］．Lung Cancer，2019，127：37-43．DOI：10.1016/j.lungcan.2018.11.021.
［56］ZHANG Y，ZENG Y Y，LIU T，et al．The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer［J］．Respir Res，2019，20（1）：164．DOI：10.1186/s12931-019-1137-4.
［57］CARBONE D P，RECK M，PAZ-ARES L，et al．First-line nivolumab in stage IV or recurrent non-small-cell lung cancer［J］．N Engl J Med，2017，376（25）：2415-2426．DOI：10.1056/NEJMoa1613493.
［58］SNYDER A，MAKAROV V，MERGHOUB T，et al．Genetic basis for clinical response to CTLA-4 blockade in melanoma［J］．N Engl J Med，2014，371（23）：2189-2199．DOI：10.1056/NEJMoa1406498.
［59］OFFIN M，RIZVI H，TENET M，et al．Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers［J］．Clin Cancer Res，2019，25（3）：1063-1069．DOI：10.1158/1078-0432.ccr-18-1102.
［60］SINGH M，JADHAV H R.Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors［J］．Drug Discov Today，2018，23（3）：745-753．DOI：10.1016/j.drudis.2017.10.004.
［61］LIANG H R，PAN Z K，WANG W，et al．The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy：a literature-based pooled analysis［J］．J Thorac Dis，2018，10（4）：2311-2320．DOI：10.21037/jtd.2018.03.150.
［62］LIANG H R，LI C C，ZHAO Y，et al．Concomitant mutations in EGFR 19Del/L858R mutation and their association with response to EGFR-TKIs in NSCLC patients［J］．Cancer Manag Res，2020，12：8653-8662．DOI：10.2147/cmar.s255967.
［63］HASTINGS K，YU H A，WEI W，et al．EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer［J］．Ann Oncol，2019，30（8）：1311-1320．DOI：10.1093/annonc/mdz141.
［64］DOGAN S，SHEN R L，ANG D C，et al．Molecular epidemiology of EGFR and KRAS mutations in 3，026 lung adenocarcinomas：higher susceptibility of women to smoking-related KRAS-mutant cancers［J］．Clin Cancer Res，2012，18（22）：6169-6177．DOI：10.1158/1078-0432.CCR-11-3265.
［65］LI X，ZHANG L，JIANG D，et al．Routine-dose and high-dose icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 21-L858R mutation：the randomized，phase II，INCREASE trial［J］．Clin Cancer Res，2020，26（13）：3162-3171．DOI：10.1158/1078-0432.CCR-19-3064.
［66］谭芬来，张力，赵琼，等．国家一类新药盐酸埃克替尼的药理与临床评价［J］．中国新药杂志，2009，18（18）：1691-1694.
TAN F L，ZHANG L，ZHAO Q，et al．Pharmacology and clinical evaluation of icotinib hydrochloride［J］．Chinese Journal of New Drugs，2009，18（18）：1691-1694.
［67］SETO T，KATO T，NISHIO M，et al．Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations（JO25567）：an open-label，randomised，multicentre，phase 2 study［J］．Lancet Oncol，2014，15（11）：1236-1244．DOI：10.1016/S1470-2045（14）70381-X.
［68］SAITO H，FUKUHARA T，FURUYA N，et al．Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer（NEJ026）：interim analysis of an open-label，randomised，multicentre，phase 3 trial［J］．Lancet Oncol，2019，20（5）：625-635．DOI：10.1016/s1470-2045（19）30035-x.
［69］ZHOU Q，WU Y L，CHENG Y，et al．CTONG 1509：phase 3 study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC［C］．Britain：Oxford University Press（OUP），2019：v603．DOI：10.1093/annonc/mdz260.002.
［70］CHENG Y，MURAKAMI H，YANG P C，et al．Randomized phaseⅡ trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations［J］．J Clin Oncol，2016，34（27）：3258-3266．DOI：10.1200/JCO.2016.66.9218.
［71］ HAN B，JIN B，CHU T，et al．Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations：a randomized controlled trial［J］．Int J Cancer，2017，141（6）：1249-1256．DOI：10.1002/ijc.30806.
［72］ZHAO Y，LIU J T，CAI X Y，et al．Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated，non-small cell lung cancer：systematic review and network meta-analysis［J］．BMJ，2019，367：l5460．DOI：10.1136/bmj.l5460.
［73］WANG S Y，YAN B，ZHANG Y W，et al．Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation［J］．Int J Cancer，2019，144（11）：2880-2886．DOI：10.1002/ijc.32015.
［74］SORIA J C，OHE Y，VANSTEENKISTE J，et al．Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer［J］．N Engl J Med，2018，378（2）：113-125．DOI：10.1056/NEJMoa1713137.
［75］QIN Q，LI X Q，LIANG X M，et al．CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer（NSCLC）［J］．Thorac Cancer，2020，11（9）：2389-2397．DOI：10.1111/1759-7714.13521.
［76］NIE H，ZHOU X，SHUZHANG D，et al．Palbociclib overcomes afatinib resistance in non-small cell lung cancer［J］．Biomed Pharmacother，2019，109：1750-1757．DOI：10.1016/j.biopha.2018.10.170.
［77］LAI G G Y，LIM T H，LIM J，et al．Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer［J］．J Clin Oncol，2019，37（11）：876-884．DOI：10.1200/JCO.18.00177.
［78］ WU Y L，CHENG Y，ZHOU J，et al．Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor （INSIGHT study）：an open-label，phase 1b/2，multicentre，randomised trial［J］．Lancet Respir Med，2020，8（11）：1132-1143．DOI：10.1016/S2213-2600（20）30154-5.
［79］WU Y L，ZHANG L，KIM D W，et al．Phase ib/II study of capmatinib（INC280）plus gefitinib after failure of epidermal growth factor receptor（EGFR）inhibitor therapy in patients with EGFR-mutated，MET factor-dysregulated non-small-cell lung cancer［J］．J Clin Oncol，2018，36（31）：3101-3109．DOI：10.1200/JCO.2018.77.7326.
［80］SEQUIST L V，HAN J Y，AHN M J，et al．Osimertinib plus savolitinib in patients with EGFR mutation-positive，MET-amplified，non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors：interim results from a multicentre，open-label，phase 1b study［J］．Lancet Oncol，2020，21（3）：373-386．DOI：10.1016/S1470-2045（19）30785-5.
［81］ZOU Q，ZHAN P，LV T，et al．The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy：a meta-analysis［J］．Transl Lung Cancer Res，2015，4（6）：792-796．DOI：10.3978/j.issn.2218-6751.2015.12.09.
［82］LI X Z，WANG S J，LI B T，et al．BIM deletion polymorphism confers resistance to osimertinib in EGFR T790M lung cancer：a case report and literature review［J］．Target Oncol，2018，13（4）：517-523．DOI：10.1007/s11523-018-0573-2.
［83］LIU S T，HE Y Y，JIANG T，et al．EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism［J］．Lung Cancer，2018，120：82-87．DOI：10.1016/j.lungcan.2018.04.004.
［84］CHEN H，WANG Y，LIN C，et al．Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction［J］．Oncotarget，2017，8（55）：93825-93838．DOI：10.18632/oncotarget.21225.
［85］ZHANG Z H，ZHANG Y，LUO F，et al．Dual blockade of EGFR and VEGFR pathways：results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer［J］．Clin Transl Med，2020，10（2）：e33．DOI：10.1002/ctm2.33.
［86］HUANG D Z，ZHONG D S，ZHANG C Y，et al．Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer（NSCLC）patients harboring activating EGFR mutations（ALTER-L004）［J］．J Clin Oncol，2020，38（15_suppl）：9573．DOI：10.1200/JCO.2020.38.15_suppl.9573.
［87］HAN B H，JIN B，CHU T Q，et al．Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations：a randomized controlled trial［J］．Int J Cancer，2017，141（6）：1249-1256．DOI：10.1002/ijc.30806.
［88］HOSOMI Y，MORITA S，SUGAWARA S，et al．Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor：NEJ009 study［J］．J Clin Oncol，2020，38（2）：115-123．DOI：10.1200/jco.19.01488.
［89］LIU S，HE Y，JIANG T，et al．EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism［J］． Lung Cancer，2018，120：82-87．DOI：10.1016/j.lungcan.2018.04.004.
［90］RAMALINGAM S S，VANSTEENKISTE J，PLANCHARD D，et al．Overall survival with osimertinib in untreated，EGFR-mutated advanced NSCLC［J］．N Engl J Med，2020，382（1）：41-50．DOI：10.1056/nejmoa1913662.
［91］PLANCHARD D，FENG P，KARASEVA N，et al.Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation（EGFRm）-positive advanced NSCLC：safety run-in results from the FLAURA2 study［J］．Annals of Oncology，2020，31（suppl_4）：S754-840．https：//oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/osimertinib-plus-platinum-pemetrexed-in-newly-diagnosed-egfr-mutation-egfrm-positive-advanced-nsclc-safety-run-in-results-from-the-flaura2-study.
［92］ZENG L，XIAO L L，JIANG W J，et al．Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population［J］．Lung Cancer，2020，141：82-88．DOI：10.1016/j.lungcan.2020.01.009.
［93］WANG Z F，REN S X，LI W，et al．Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R：a systematic review and meta-analysis［J］．BMC Cancer，2018，18（1）：148．DOI：10.1186/s12885-018-4075-5.
［94］YU H A，SCHOENFELD A J，MAKHNIN A，et al．Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers：a phase 1/2 single-group open-label trial［J］．JAMA Oncol，2020，6（7）：1048-1054．DOI：10.1001/jamaoncol.2020.1260.
［95］NAKAGAWA K，GARON E B，SETO T，et al．Ramucirumab plus erlotinib in patients with untreated，EGFR-mutated，advanced non-small-cell lung cancer（RELAY）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］．Lancet Oncol，2019，20（12）：1655-1669．DOI：10.1016/s1470-2045（19）30634-5.
［96］ZHONG D，ZHANG C，ZHANG Y，et al．Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study［J］．Annals of Oncology，2020，31（suppl_4）：S754-840．https：//oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/anlotinib-combined-with-icotinib-provides-a-promising-first-line-treatment-option-for-egfr-positive-nsclc-patients-harboring-concomitant-mutations.
［97］ROTOW J K，COSTA D B，PAWELETZ C P，et al．Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer（NSCLC）［J］．J Clin Oncol，2020，38（15_suppl）：9507．DOI: 10.1200/JCO.2020.38.15_suppl.9507.
［98］LO Y M，ZHANG J，LEUNG T N，et al．Rapid clearance of fetal DNA from maternal plasma［J］．Am J Hum Genet，1999，64（1）：218-224．DOI：10.1086/302205.
［99］MOK T，WU Y L，LEE J S，et al．Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy［J］．Clin Cancer Res，2015，21（14）：3196-3203．DOI：10.1158/1078-0432.CCR-14-2594.